title: Splenic infarction and bevacizumab.
authors.affiliation: Gustave Roussy Institute, Villejuif, France. malka@igr.fr
authors.forename: David
authors.initials: D
authors.lastname: Malka
authors.forename: Marc
authors.initials: M
authors.lastname: Van den Eynde
authors.forename: Valérie
authors.initials: V
authors.lastname: Boige
authors.forename: Clarisse
authors.initials: C
authors.lastname: Dromain
authors.forename: Michel
authors.initials: M
authors.lastname: Ducreux
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000556:secondary; D020533:Angiogenesis Inhibitors / Q000009:adverse effects*; D000911:Antibodies, Monoclonal / Q000009:adverse effects*; D061067:Antibodies, Monoclonal, Humanized; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D000068258:Bevacizumab; D006801:Humans; D008297:Male; D008875:Middle Aged; D013159:Splenic Infarction / Q000209:etiology* / Q000473:pathology; D042461:Vascular Endothelial Growth Factor A / Q000378:metabolism
chemical_list: D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D042461:Vascular Endothelial Growth Factor A; D000068258:Bevacizumab